This program is intended for healthcare professionals outside the United States only.
Late-onset genetic cholestasis
Login
Register
This program is intended for healthcare professionals outside the United States only.
Popular searches
Popular searches

EASL 2026 Reflections: Key takeaways in late-onset genetic cholestasis and Alagille syndrome

  • EASL 2026, Late Onset Genetic Cholestasis, Video
Leave your feedback

Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.

This video offers subtitles in English, French, Portuguese, and Spanish, which can be enabled using the subtitle icon  in the video player.

Enjoyed this? You might like:

  • Video
  • EASL 2026

Evolving therapeutic approaches in late-onset genetic cholestasis

Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.
Watch now
  • News article
  • EASL 2026

Observational data show IBAT inhibitor promise for pruritus in late-onset PFIC and ICP

Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.
Find out more
  • News article
  • EASL 2026

Intrahepatic cholestasis of pregnancy recurs in 4 in 10 pregnancies

Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.
Find out more
  • Video
  • EASL 2026

Uncovering hidden genetic causes in adult cholestasis

Jeremy Nayagam highlights research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis and explains why such testing is important in the diagnosis of these patients.
Watch now
  • News article
  • EASL 2026

Case series suggests IBAT inhibitor benefits in adults with hereditary BSEP deficiency

Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.
Find out more
  • News article
  • EASL 2026

Targeted gene sequencing panel resolves unexplained cholestasis in about 5% of adults

A targeted next generation sequencing gene panel could offer a definitive diagnosis for some adults with unexplained cholestasis.
Find out more
  • News article
  • EASL 2026

Researchers call for ICP to be included in hepatobiliary risk stratification

Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.
Find out more
  • News article
  • EASL 2026

Bilirubin and platelet count predict native liver survival in adolescents with ALGS

Researchers identify factors predicting improved native liver survival in adolescents with Alagille syndrome.
Find out more
  • News article
  • EASL 2026

Genetic variants explain substantial proportion of undiagnosed cholestasis and hepatitis

Study findings support early genetic testing for unexplained idiopathic chronic cholestasis and hepatitis of unknown origin.
Find out more
  • Video
  • AASLD 2025

AASLD 2025 Reflections: Key takeaways in primary sclerosing cholangitis

Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.
Watch now
Primary Sclerosing Cholangitis (PSC)